Dr. Mohammed Salhab, MD

Dr. Salhab practices at Regional West Medical Center in Scottsbluff, Nebraska, part of Regional West Health Services.

Dr. Salhab's NPI, 1831454149, was assigned on July 12, 2012. Dr. Salhab holds Colorado license DR.0066986.

Dr. Salhab's primary practice is Regional West Medical Center, at 4021 Ave B, Scottsbluff, NE 69361 in Scott Bluff County. The practice phone is (308) 635-3711.

Dr. Salhab's primary practice is Regional West Medical Center in Scottsbluff, Nebraska, part of Regional West Health Services. Dr. Salhab is also affiliated with AdventHealth Porter. The medical group on file is Regional West Physicians Clinic-Women's Center. Dmand AI also links Dr. Salhab to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Salhab practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Salhab's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Salhab's licenses on file in 2 states: Colorado and Massachusetts.

CMS data shows 511 Medicare services from Dr. Salhab across 7 procedure codes in 2024, for 206 Medicare patients. Medicare paid $54,287 for them.

CMS counts 206 Medicare patients who saw Dr. Salhab in 2024. The largest group is 65 to 74, with 78 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 16% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Salhab's median patient age at 73, with 49% women.

In 2024, Dr. Salhab wrote 260 Medicare Part D claims for 91 patients. 79% of them were for generic drugs. CMS names the drug for 62 of them, across 3 drugs with 11 or more claims each, at $22,981 in total drug cost. In 2023, CMS named 109 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Salhab for performance year 2024, reported as part of a group. Dr. Salhab accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Salhab as offering telehealth.

Dmand AI links 8 papers to Dr. Salhab, published from 2014 to 2018. 2018 was the busiest year, with 3. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Hematopoietic Stem Cell Transplantation and Lymphoma, Large B-Cell, Diffuse. Dr. Salhab has published most often in Leuk Lymphoma. Dr. Salhab's most frequent co-authors are Veronika Bachanova, MD, Martha Jane Glenn, MD and Francisco J. Hernandez-Ilizaliturri, MD.

Dmand AI links Dr. Salhab to 3 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Small Cell Lung Carcinoma. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 137 general payments to Dr. Salhab from 48 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 58% of the total. Boston Scientific Corporation paid the most, $2,124.